Drug Trial Radar · NCT02102204
Extension Study of Etelcalcetide for Treatment of Secondary Hyperparathyroidism in Patients With Chronic Kidney Disease on Hemodialysis
Last checked: Nov 20, 2026Latest source record: Nov 17, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
902
Actual
Start
Mar 25, 2014
Primary completion
Nov 4, 2016
Study completion Jun 26, 2017
Sponsor
- Lead sponsor
- AmgenAmgen (AMGN)
- Sponsor type
- Industry
- First posted
- Apr 2, 2014
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 110 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, single-arm, extension study to characterize the long-term safety and tolerability of etelcalcetide in the treatment of Secondary Hyperparathyroidism (SHPT) in adults with Chronic Kidney Disease (CKD) on hemodialysis.
Conditions
- Hyperparathyroidism, Secondary
Interventions
EtelcalcetideDrug
Etelcalcetide was supplied as a sterile, preservative-free, ready-to-administer aqueous solution.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Adverse EventsTime frame: From the date of first dose of etelcalcetide (in the current study) and up to 30 days after the last dose; median duration of treatment was 563 days.
Locations
228 sites in 24 countries. Site status is shown where the registry gives one.
Research Site
Birmingham, Alabama
Research Site
Alhambra, California
Research Site
Azusa, California
Research Site
Bakersfield, California
Research Site
Cudahy, California
Research Site
Granada Hills, California
Research Site
Los Angeles, California
Research Site
Los Angeles, California
Research Site
Northridge, California
Research Site
Riverside, California
Research Site
Simi Valley, California
Research Site
Vacaville, California
Research Site
Whittier, California
Research Site
Aurora, Colorado
Research Site
Westminster, Colorado
Research Site
Stamford, Connecticut
Research Site
Miami, Florida
Research Site
Ocala, Florida
Research Site
Pembroke Pines, Florida
Research Site
Tampa, Florida
Research Site
Augusta, Georgia
Research Site
Dublin, Georgia
Research Site
Meridian, Idaho
Research Site
Highland Park, Illinois
Research Site
Merrillville, Indiana
Research Site
Michigan City, Indiana
Research Site
Wichita, Kansas
Research Site
Baton Rouge, Louisiana
Research Site
Springfield, Massachusetts
Research Site
Detroit, Michigan
Research Site
Pontiac, Michigan
Research Site
Brookhaven, Mississippi
Research Site
Columbus, Mississippi
Research Site
Gulfport, Mississippi
Research Site
Tupelo, Mississippi
Research Site
Kansas City, Missouri
Research Site
Lincoln, Nebraska
Research Site
Las Vegas, Nevada
Research Site
Reno, Nevada
Research Site
Eatontown, New Jersey
Showing 40 of 228 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.